BiotechTube
MedinCell

MedinCell

Montpellier, France· Est.
medincell.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $285M

Overview

MedinCell is a clinical-stage biotech company with a commercial-stage product, specializing in long-acting injectable drug delivery via its proprietary BEPO® technology. The company has successfully partnered with major pharmaceutical firms like Teva, leading to the FDA-approved schizophrenia treatment UZEDY® and a late-stage pipeline including a promising olanzapine LAI. With a recent ~€48 million private placement and a growing revenue stream from its partnered product, MedinCell is positioned to expand its impact in psychiatry and other therapeutic areas while advancing its internal pipeline.

PsychiatrySchizophrenia

Technology Platform

Proprietary BEPO® technology for long-acting injectable (LAI) drug delivery, enabling controlled release of therapeutics from one week to several months.

Funding History

5
Total raised:$285M
IPO$60M
IPO$75M
Series C$60M
Series C$50M

Opportunities

The strong commercial growth of UZEDY® validates the BEPO® platform and provides expanding royalty revenue.
The upcoming potential approval and launch of mdc-TJK, with its differentiated safety profile, could capture a significant share of the olanzapine LAI market.
The versatile BEPO® technology platform allows for expansion into new therapeutic areas beyond psychiatry.

Risk Factors

High dependency on the regulatory and commercial success of a single late-stage asset (mdc-TJK).
Revenue is largely dependent on the performance of partner Teva Pharmaceuticals, limiting direct control.
The long-acting injectable market, particularly in schizophrenia, is competitive with several established products.

Competitive Landscape

MedinCell competes in the long-acting injectable antipsychotic market against companies like Johnson & Johnson (Invega Sustenna/Trinza), Alkermes (Aristada), and Otsuka/Lundbeck (Abilify Maintena). Its key differentiation is the proprietary BEPO® technology, which aims to offer favorable safety profiles (e.g., no PDSS risk for olanzapine) and flexible dosing. Competition also comes from other drug delivery technology companies developing sustained-release formulations.

More companies in Drug Delivery & Formulation →More companies in France →